Aptamer: toxin conjugates that specifically target prostate tumor cells
TC Chu, JW Marks III, LA Lavery, S Faulkner… - Cancer research, 2006 - AACR
TC Chu, JW Marks III, LA Lavery, S Faulkner, MG Rosenblum, AD Ellington, M Levy
Cancer research, 2006•AACRWe have used RNA aptamer: gelonin conjugates to target and specifically destroy cells
overexpressing the known cancer biomarker prostate-specific membrane antigen (PSMA).
Aptamer: toxin conjugates have an IC50 of 27 nmol/L and display an increased potency of at
least 600-fold relative to cells that do not express PSMA. The aptamer not only promotes
uptake into target cells but also decreases the toxicity of gelonin in non-target cells. These
results validate the notion that “escort aptamers” may be useful for the treatment of specific …
overexpressing the known cancer biomarker prostate-specific membrane antigen (PSMA).
Aptamer: toxin conjugates have an IC50 of 27 nmol/L and display an increased potency of at
least 600-fold relative to cells that do not express PSMA. The aptamer not only promotes
uptake into target cells but also decreases the toxicity of gelonin in non-target cells. These
results validate the notion that “escort aptamers” may be useful for the treatment of specific …
Abstract
We have used RNA aptamer:gelonin conjugates to target and specifically destroy cells overexpressing the known cancer biomarker prostate-specific membrane antigen (PSMA). Aptamer:toxin conjugates have an IC50 of 27 nmol/L and display an increased potency of at least 600-fold relative to cells that do not express PSMA. The aptamer not only promotes uptake into target cells but also decreases the toxicity of gelonin in non-target cells. These results validate the notion that “escort aptamers” may be useful for the treatment of specific tumors expressing unique antigen targets.(Cancer Res 2006; 66(12): 5989-92)
AACR